Hair loss is a common worry during treatment with Ozempic, Wegovy, or Mounjaro. The timing can feel suspicious. A person starts treatment, loses weight, then notices more hair in the shower or on a brush a few months later.
The key point is this: hair shedding during treatment is real, but current evidence does not prove that these medicines directly damage hair follicles. For many patients, the most likely explanation is telogen effluvium, a temporary shedding pattern that can follow rapid weight loss, low energy intake, illness, childbirth, surgery, or nutritional stress.
Élan's view: healthy treatment is not the fastest possible weight loss. It is fat loss with enough nutrition, muscle preservation, and a realistic plan for long-term maintenance.
What telogen effluvium means
Hair grows in cycles. At any time, some follicles grow and some rest. Telogen effluvium happens when a stressor pushes more follicles than usual into the resting phase. The shedding usually becomes visible two to four months after the trigger.
Rapid weight loss is a known trigger. GLP-1 based treatment can reduce appetite strongly. If the patient eats too little protein, too few total calories, or misses key nutrients, the body may treat this as a stress signal.
The good news: telogen effluvium itself is usually non-scarring. The follicle is not destroyed. Hair often improves after weight loss and nutrition stabilise.
The caution: not every hair-loss pattern is telogen effluvium. Androgenetic alopecia, thyroid disease, iron deficiency, inflammatory scalp disease, postpartum changes, medication changes, and scarring alopecias can overlap or appear at the same time.
What the evidence says
Several recent reviews describe an association between GLP-1 based treatment and alopecia reports, especially with semaglutide and tirzepatide. The evidence is still mostly observational, pharmacovigilance-based, or review-based. That means it can identify signals, but it cannot prove direct causality for every patient.
A 2026 review by Piraccini and colleagues in Dermatology and Therapy concluded that causality has not been established and that telogen effluvium related to rapid weight loss is a plausible mechanism.
A 2026 scoping review by Zarabian and colleagues in Dermatologic Surgery found that telogen effluvium and androgenetic alopecia were the main patterns reported across the available literature.
A 2026 systematic review by Gupta and colleagues in Science Progress described telogen effluvium as the predominant reported subtype and noted that reports appeared more common at higher obesity-treatment maintenance doses than at lower diabetes-treatment doses.
A 2026 cross-sectional study by Argobi and colleagues in the Journal of Cosmetic Dermatology studied 254 patients using GLP-1 based treatment. It was useful as a signal study, but because it was questionnaire-based and cross-sectional, it cannot prove causality or estimate an individual patient's risk precisely.
A 2025 systematic review by Alsuwailem and colleagues reviewed five studies covering 2,905 adult patients and found mixed results, including some patients who reported improved hair condition. The evidence quality varied, which supports caution against simple explanations.
What Élan would look at
At Élan, the question is not only whether the medicine is involved. The better question is: what changed in the body during treatment?
- how fast weight was lost
- whether the patient is eating enough protein
- whether intake has become too restrictive
- menstrual blood loss or symptoms of anaemia
- ferritin and iron studies when indicated
- complete blood count when clinically relevant
- thyroid function when symptoms or history suggest it
- vitamin D, B12, zinc, or other tests selectively, not automatically for everyone
- recent illness, surgery, childbirth, infection, or major stress
- the scalp pattern: diffuse shedding, patchy loss, inflammation, scarring signs, or androgenetic pattern
Ferritin testing is reasonable in patients with hair shedding, heavy menstrual bleeding, restrictive intake, anaemia symptoms, or other risk factors. Routine supplement stacks are not the answer for everyone.
Biotin deserves special caution. True biotin deficiency is uncommon. Routine high-dose biotin is not usually needed, and biotin can interfere with some blood tests, including thyroid and cardiac tests. Patients taking biotin should tell their clinician before blood tests.
Iron, vitamin D, zinc, and other supplements should usually be based on deficiency, risk factors, or clinician advice. More supplements is not automatically safer.
What patients can do
Do not stop treatment suddenly because of hair shedding without discussing it. Abrupt stopping can increase the risk of weight regain, which is the opposite of good long-term care.
- Tell your clinician when shedding started and how fast weight has changed.
- Check whether your food intake has become too low.
- Prioritise protein, resistance training, and steady maintenance habits.
- Ask whether selective blood tests make sense for you.
- Seek dermatology assessment if hair loss is patchy, scarring, painful, inflamed, or not improving.
When to seek urgent or specialist help
Most diffuse shedding is not an emergency. But you should seek medical assessment if you notice patchy hair loss, scalp pain, redness, scaling, pustules, signs of scarring, sudden severe shedding, hair loss with systemic symptoms, or no improvement after weight and nutrition stabilise.
Bottom line
Hair shedding during GLP-1 treatment can be frightening, but it is often explainable. The leading explanation for diffuse shedding is telogen effluvium linked to rapid weight loss or nutritional stress. Direct drug causality has not been proven, and other causes should not be missed.
Good weight treatment is not only about losing weight. It is about keeping the result, protecting muscle, maintaining nutrition, and avoiding preventable side effects.
If you are using Ozempic, Wegovy, or Mounjaro and hair shedding is worrying you, book a medical consultation with Élan Clinic to review your treatment pace, nutrition, risk factors, and maintenance plan.
Sources
- Piraccini BM et al., Dermatology and Therapy, 2026. DOI: 10.1007/s13555-026-01792-0.
- Zarabian D et al., Dermatologic Surgery, 2026. DOI: 10.1097/DSS.0000000000005176.
- Gupta A et al., Science Progress, 2026. DOI: 10.1177/00368504261444578.
- Alsuwailem A et al., Cureus, 2025. DOI: 10.7759/cureus.92454.
- Argobi YA et al., Journal of Cosmetic Dermatology, 2026. DOI: 10.1111/jocd.70835.